BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1238 related articles for article (PubMed ID: 24122735)

  • 21. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010.
    Gozali AE; Britt B; Shane L; Gonzalez I; Gilles F; McComb JG; Krieger MD; Lavey RS; Shlien A; Villablanca JG; Erdreich-Epstein A; Dhall G; Jubran R; Tabori U; Malkin D; Finlay JL
    Pediatr Blood Cancer; 2012 Jun; 58(6):905-9. PubMed ID: 21990040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.
    Macedo GS; Araujo Vieira I; Brandalize AP; Giacomazzi J; Inez Palmero E; Volc S; Rodrigues Paixão-Côrtes V; Caleffi M; Silva Alves M; Achatz MI; Hainaut P; Ashton-Prolla P
    Cancer Genet; 2016 Mar; 209(3):97-106. PubMed ID: 26823150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of de novo and mosaic
    Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
    J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.
    Garritano S; Gemignani F; Palmero EI; Olivier M; Martel-Planche G; Le Calvez-Kelm F; Brugiéres L; Vargas FR; Brentani RR; Ashton-Prolla P; Landi S; Tavtigian SV; Hainaut P; Achatz MI
    Hum Mutat; 2010 Feb; 31(2):143-50. PubMed ID: 19877175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.
    Figueiredo BC; Sandrini R; Zambetti GP; Pereira RM; Cheng C; Liu W; Lacerda L; Pianovski MA; Michalkiewicz E; Jenkins J; Rodriguez-Galindo C; Mastellaro MJ; Vianna S; Watanabe F; Sandrini F; Arram SB; Boffetta P; Ribeiro RC
    J Med Genet; 2006 Jan; 43(1):91-6. PubMed ID: 16033918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
    Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations.
    Choong SS; Latiff ZA; Mohamed M; Lim LL; Chen KS; Vengidasan L; Razali H; Abdul Rahman EJ; Ariffin H;
    Clin Genet; 2012 Dec; 82(6):564-8. PubMed ID: 22233476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors.
    Tabori U; Shlien A; Baskin B; Levitt S; Ray P; Alon N; Hawkins C; Bouffet E; Pienkowska M; Lafay-Cousin L; Gozali A; Zhukova N; Shane L; Gonzalez I; Finlay J; Malkin D
    J Clin Oncol; 2010 Apr; 28(12):1995-2001. PubMed ID: 20308654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
    Lin MT; Shieh JJ; Chang JH; Chang SW; Chen TC; Hsu WH
    Pediatr Blood Cancer; 2009 Apr; 52(4):541-4. PubMed ID: 19101993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.
    Hwang SM; Lee ES; Shin SH; Kong SY
    Korean J Lab Med; 2008 Dec; 28(6):493-7. PubMed ID: 19127115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
    Cury NM; Ferraz VE; Silva WA
    Hered Cancer Clin Pract; 2014 Mar; 12(1):8. PubMed ID: 24625245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways.
    Meneghetti BV; Wilson R; Dias CK; Cadore NA; Klamt F; Zaha A; Ferreira HB; Monteiro KM
    Biochimie; 2022 Jul; 198():141-154. PubMed ID: 35367578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.
    Raymond VM; Else T; Everett JN; Long JM; Gruber SB; Hammer GD
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E119-25. PubMed ID: 23175693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
    Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
    Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
    Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
    J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
    Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.